Skip to content

Paratek buy reiterated by Cantor

July 17, 2017

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK)‘s stock had its “overweight” rating restated by equities researchers at Cantor Fitzgerald in a research note issued to investors on Thursday, June 22nd. They presently have a $50.00 price objective on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s price target indicates a potential upside of 107.90% from the company’s current price.


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: